ASCO 2022 Annual Meeting
Advertisement
Improving access to evidence-based information for caregivers could improve outcomes for patients with breast cancer.
Andrea Sbrana and colleagues presented results of a nationwide, open-label study conducted in 29 Italian centers.
Kathi Mooney, PhD, RN, reported the results of a study looking at the combined intervention at the 2022 ASCO Annual Meeting.
The results were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Just 38% of patients with breast cancer receive at least 1 palliative care consult following metastatic disease diagnosis.
All stakeholders have a role to play in increasing representation in this patient population.
A study identified self-reported gaps from healthcare providers associated with providing treatment-related support.
Patients with head and neck cancers may derive benefit from receiving oncology nurse navigation.
"Early identification of patient illness may help reduce acute care use and improve quality of care.”
Research has shown that weight gain and obesity can be associated with an increased risk of developing breast cancer.
Some research has shown that patients with certain autoimmune diseases have a lower risk of breast cancer.
“CTCs contribute to the metastatic cascade and represent an independent survival predictor in breast cancer."
Research has shown that women with breast cancer who live in socioeconomically disadvantaged areas have poorer outcomes.
Breast cancer that is hormone receptor (HR)-positive tends to be diagnosed early, when it is highly treatable.
The new research was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Younger patients with breast cancer tend to have a poorer prognosis and higher rates of recurrence.
Many low-income areas of the world still experience poor outcomes and lack information to guide improvements.
A study examined the effectiveness of adding pyrotinib, a new tyrosine kinase inhibitor (TKI).
Identification of human epidermal growth factor receptor 2 status is important in breast cancer diagnosis.
Much research has examined the effects of body mass index (BMI) on breast cancer risk and outcomes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.